Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Non-Current Liabilities (2019 - 2025)

Allogene Therapeutics' Total Non-Current Liabilities history spans 7 years, with the latest figure at $109.0 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 7.42% year-over-year to $109.0 million; the TTM value through Sep 2025 reached $109.0 million, down 7.42%, while the annual FY2024 figure was $118.8 million, 5.31% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $109.0 million at Allogene Therapeutics, down from $110.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $153.1 million in Q1 2023 and bottomed at $95.9 million in Q1 2022.
  • The 5-year median for Total Non-Current Liabilities is $118.8 million (2024), against an average of $122.8 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 59.69% in 2023 before it decreased 21.74% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $118.1 million in 2021, then increased by 23.08% to $145.4 million in 2022, then fell by 13.72% to $125.4 million in 2023, then dropped by 5.31% to $118.8 million in 2024, then dropped by 8.25% to $109.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Total Non-Current Liabilities are $109.0 million (Q3 2025), $110.9 million (Q2 2025), and $111.3 million (Q1 2025).